412 related articles for article (PubMed ID: 1967823)
1. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.
MacLennan DH; Duff C; Zorzato F; Fujii J; Phillips M; Korneluk RG; Frodis W; Britt BA; Worton RG
Nature; 1990 Feb; 343(6258):559-61. PubMed ID: 1967823
[TBL] [Abstract][Full Text] [Related]
2. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2.
McCarthy TV; Healy JM; Heffron JJ; Lehane M; Deufel T; Lehmann-Horn F; Farrall M; Johnson K
Nature; 1990 Feb; 343(6258):562-4. PubMed ID: 2300206
[TBL] [Abstract][Full Text] [Related]
3. [What significance to genotype changes have in diagnosis of malignant hyperthermia?].
Steinfath M; Scholz J; Singh S; Wappler F
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Aug; 31(6):334-43. PubMed ID: 8962927
[TBL] [Abstract][Full Text] [Related]
4. The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia.
MacLennan DH; Otsu K; Fujii J; Zorzato F; Phillips MS; O'Brien PJ; Archibald AL; Britt BA; Gillard EF; Worton RG
Symp Soc Exp Biol; 1992; 46():189-201. PubMed ID: 1341035
[TBL] [Abstract][Full Text] [Related]
5. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
[TBL] [Abstract][Full Text] [Related]
6. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
[TBL] [Abstract][Full Text] [Related]
8. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
[TBL] [Abstract][Full Text] [Related]
9. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia.
Anderson AA; Brown RL; Polster B; Pollock N; Stowell KM
Anesthesiology; 2008 Feb; 108(2):208-15. PubMed ID: 18212565
[TBL] [Abstract][Full Text] [Related]
10. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
[TBL] [Abstract][Full Text] [Related]
11. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
Monnier N; Lunardi J
Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
[TBL] [Abstract][Full Text] [Related]
12. Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree.
Moslehi R; Langlois S; Yam I; Friedman JM
Am J Med Genet; 1998 Feb; 76(1):21-7. PubMed ID: 9508059
[TBL] [Abstract][Full Text] [Related]
13. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors.
Censier K; Urwyler A; Zorzato F; Treves S
J Clin Invest; 1998 Mar; 101(6):1233-42. PubMed ID: 9502764
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
Wehner M; Rueffert H; Koenig F; Olthoff D
Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
[TBL] [Abstract][Full Text] [Related]
15. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
[TBL] [Abstract][Full Text] [Related]
16. Several interacting genes influence the malignant hyperthermia phenotype.
Robinson R; Hopkins P; Carsana A; Gilly H; Halsall J; Heytens L; Islander G; Jurkat-Rott K; Müller C; Shaw MA
Hum Genet; 2003 Feb; 112(2):217-8. PubMed ID: 12522565
[TBL] [Abstract][Full Text] [Related]
17. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.
Tong J; Oyamada H; Demaurex N; Grinstein S; McCarthy TV; MacLennan DH
J Biol Chem; 1997 Oct; 272(42):26332-9. PubMed ID: 9334205
[TBL] [Abstract][Full Text] [Related]
18. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
[TBL] [Abstract][Full Text] [Related]
19. Novel ryanodine receptor mutation that may cause malignant hyperthermia.
Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG
Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443
[TBL] [Abstract][Full Text] [Related]
20. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
